Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacy.

Heartcenter Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, The Netherlands; University of Copenhagen, Copenhagen, Denmark; Mount Sinai Medical Center, New York, NY, USA; Department of Medicine, Oslo University Hospital and Oslo University, 0514 Oslo, Norway; Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK; Henry Ford Hospital, Detroit, MI, USA; Thoraxcenter, Erasmus University Medical Center, Rotterdam, The Netherlands; State University of New York Downstate Medical Center, Brooklyn, NY, USA; Boehringer-Ingelheim, Paris, France; Johnson & Johnson Pharmaceutical Research and Development, Raritan, NJ, USA; The Medicines Company, Munich, Germany; Western Infirmary and the British Heart Foundation, Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK; Bayer HealthCare Pharmaceuticals, Montville, NJ, USA; Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA; INSERM, Centre d’Investigation Clinique 9501 and Unité 961, Centre Hospitalier Universitaire, Nancy, France; Department of Cardiology, Nancy University, Nancy, France; and INSERM CHU, Hôpital Jeanne d’ Arc, 54200 Toul., Nancy, France